108 results about "Peptide ligand" patented technology

The invention discloses an active oxygen scavenging drug-loaded targeted nano delivery platform based on diselenide bond bridging as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the invention, tetra (4-carboxyphenyl) porphyrin (TCPP) and manganese porphyrin (Mn-TCPP) are used as raw materials to synthesize an organic metal framework MOFs, a target drug is loaded on the MOFs through electrostatic adsorption / blending, and amino and diselenide bonds are linked on the MOFs to realize combination with a specific peptide ligand and promote release of a drug oxidative stress microenvironment. The nano delivery platform with specific targeting and ROS response performance is obtained. The specific treatment effect of different diseases is achieved through different selections of the loaded drugs and the specific peptide ligands.

Methods and apparatus for determining protein and ligand sequence, structure, and docking site given a target protein sequence and structure are presented. A multicapitate transformer architecture with a number of heads including a sequence head and a structure head is introduced, wherein given a target protein sequence and structure, a candidate ligand is generated, wherein the transformer's sequence head yields the ligand sequence and the structure head yields the ligand structure and docking site. Non-capitate weights are shared between the output heads. In one embodiment, a discriminative feature localization method is used to optimize the target protein's input structure representation towards the desired ligand effect class. The methods and apparatus presented enable design and synthesis of both peptide ligands and small molecule drugs each with specified ligand effect categories.

Methods and apparatus for determining a representation of a protein-protein complex, given a constituent target complex of the protein-protein complex are presented; where the constituent target complex is some subset of the protein-protein complex. A recursive transformer neural network is devised, wherein for each iteration of the recursion, a representation of the output constituent protein complexed with the input constituent target complex is passed into the transformer as input for the next iteration. Some embodiments of the invention include design and manufacturing of effective synthetic biologic drugs, monoclonal antibody (mAb) drug, Antibody Drug Conjugate (ADC), peptide ligand drug, and small molecule drugs (SMDs).

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups which have utility in imaging and targeted cancer therapy.

The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.

The invention belongs to the technical field of biological medicine, and particularly relates to application of astaxanthin vesicles in preventing and relieving colon cancer, and the astaxanthin vesicles have at least one of the following applications: oxidation resistance; anti-inflammation; the antibacterial effect is achieved; the phagocytic ability of macrophages is promoted; the intestinal health is improved; tumor cell proliferation is resisted; preventing and / or treating tumors; the preparation method of the embedding body comprises the following steps: S1, mixing an iRGD peptide ligand, a hyaluronic acid ligand and a solution containing vesicles to obtain a carrier; s2, enabling the carrier to be in contact with astaxanthin, so as to obtain the embedding body. According to the application, the astaxanthin is embedded into the targeting carrier, so that the astaxanthin is effectively protected from being influenced by an in-vivo environment, and meanwhile, the astaxanthin is accurately targeted to target parts such as macrophages in a tumor microenvironment, so that the concentration of a medicine at a diseased region is improved, the side effect on normal tissues is reduced, and the curative effect of the medicine is improved. The astaxanthin can safely and efficiently reach a target site and exert multiple functions of oxidation, anti-inflammation, antibiosis and the like.

To provide peptide ligands, and peptide complexes comprising the peptide ligands conjugated to a second peptide.SOLUTION: The present invention provides a peptide ligand that binds to Nectin-4 present on a cancer cell, or a pharmaceutically acceptable salt thereof, the peptide ligand comprising a polypeptide comprising at least three reactive groups separated by at least two loop sequences, and a molecular scaffold that forms covalent bonds with the reactive groups of the polypeptide, such that at least two polypeptide loops are formed on the molecular scaffold, wherein the polypeptide is a modified derivative of a specific sequence.SELECTED DRAWING: None

Disclosed are compounds, compositions, and methods relating to epitope-targeted immunostimulants (EPis), which comprise a synthetic peptide ligand and an antibody-recruiting moiety. The peptide ligand binds an epitope on a target and the antibody-recruiting moiety recruits antibodies to the target when the EPI is bound to the epitope on the target. Also disclosed are compositions comprising any of the disclosed EPis. Also disclosed are methods of stimulating an immune reaction to a microorganism or other pathogen in a subject where an EPI is administered to the subject. Also disclosed are methods of identifying the peptide ligand by using multi-omic analysis.

The present disclosure relates to a lipid conjugated bivalent peptide ligand which bind to Protein Interacting with C Kinase – 1 (PICK1) and thereby inhibit PICK1. The PICK1 inhibitors of the present disclosure comprise a peptide portion comprising two peptide ligands of PICK1, and a non-peptide portion comprising a linker, linking the two peptide ligands, and a lipid. The disclosure furthermore relates to therapeutic and diagnostic use of said PICK1 inhibitor for treatment of diseases or disorders associated with maladaptive plasticity.

The present disclosure provides materials and methods related to the purification of a biologic from a biological fluid. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production of a biologic.

An affinity membrane separator is provided that includes a separation substrate with a plurality of peptide ligands positioned thereon. The peptide ligands preferentially bind to one of a nucleic acid product and a waste nucleic acid product, e.g., produced by a mRNA synthesis bioreactor. The peptide ligands include fewer than 20 residues and at least one defined secondary structure, and have a global charge greater than about 1 and at least one lysine, arginine, or glutamine residue in order to preferentially bind ds-RNA relative to ss-RNA, or a global charge less than about 0 and at least one serine or asparagine residue in order to preferentially bind ss-RNA relative to ds-RNA. Peptide ligands can advantageously bind to ds-RNA byproducts from the production of ss-RNA vaccines, e.g., against SARS-CoV-2, while allowing the ss-RNA vaccines themselves to pass through the separator, providing an efficient system for production of purified ss-RNA vaccine products.

Described herein are methods for enriching, identifying, quantifying, and / or characterizing a protein of interest in a complex biological sample, such as a serum sample. The protein of interest may be enriched using a library of bead-based peptide ligands. The enriched protein of interest may subsequently be subjected to denaturation, reduction, and / or enzymatic digestion, to generate peptides which can be detected using liquid chromatography-mass spectrometry (LC-MS) techniques, and which are uniquely identifying of the protein of interest.

The present invention relates to a heterotandem acyclic peptide complex comprising a first peptide ligand that binds to a component present on an immune cell, which is conjugated via a linker to a second peptide ligand that binds to a component present on a cancer cell. The present invention also relates to the use of said heterotandem acyclic peptide complex in preventing, inhibiting, or treating cancer.

The present disclosure provides materials and methods related to the purification of viral vectors. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production and purification of adeno-associated viruses (AAVs).

The invention discloses an affinity peptide ligand for separation and purification of a VSV-G pseudotype lentiviral vector and application of the affinity peptide ligand. The affinity peptide ligand contains an amino acid sequence combined with a VSV-G pseudotype lentiviral vector envelope protein; the amino acid sequence is any one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7 and SEQ ID NO. 8. A biological raw material solution containing VSV-G pseudotype lentivirus vector components flows into the affinity chromatography medium, and after adsorption and cleaning, a target vector can be collected through a mild elution step; the recovery rate of virus vector particles is 78% or above, the removal rate of Vero host cell impure protein is 90% or above, the double-stranded DNA residue is 48% or below, and the separation effect is very remarkable.

Methods for determining a representation of a protein complex, given a constituent target complex of that protein complex are presented; where the constituent target complex is a single entity constituent or subcomplex of the protein complex; and wherein a protein complex is a complex of some combination of one or more of proteins, nucleic acids, metal ions, and small molecules. A recursive neural network is devised, wherein for each iteration of the recursion, a representation of the output constituent of the protein complex together with the input constituent target complex is passed into the neural network as input for the next iteration. Some embodiments of the invention include design and manufacturing of effective synthetic biologic drugs, monoclonal antibody (mAb) drug, Antibody Drug Conjugate (ADC), peptide ligand drug, and small molecule drugs (SMDs).

The present invention relates to a novel peptide that specifically binds to nucleolin, and more specifically, to a peptide expressed by a specific amino acid sequence, a conjugate comprising the peptide and an anticancer drug, a fusion peptide comprising the peptide and a cell-penetrating peptide, a composition comprising the peptide for diagnosing cancer, and a composition comprising the peptide or the conjugate for preventing or treating cancer. In the present invention, the peptide ligand AGM peptide and its mutants, screened using the MAP synthesis method and the OBOC combination method, have been shown to specifically bind to cancer cells, and their conjugates with anticancer drugs inhibit cancer growth (in vitro and in vivo). Therefore, the AGM peptide targeting nucleolin can be effectively used for diagnosis and targeted drug delivery in cancer treatment.

The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).

To provide a ligand binding to nectin-4 present on cancer cells, or a pharmaceutically acceptable salt thereof.SOLUTION: The present invention relates to heterotandem bicyclic peptide complexes comprising a first peptide ligand that binds to a component present on a cancer cell conjugated via a linker to a second peptide ligand that binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in the prevention, inhibition or treatment of cancer.SELECTED DRAWING: None

The present disclosure provides compositions and methods related to the purification and / or isolation of antibodies. In particular, the present disclosure provides novel peptide ligands capable of targeting the fragment antigen binding (Fab) domain and / or single-chain variable fragment (scFv) of antibodies to facilitate the isolation and / or purification of antibodies from processing fluid streams. The novel ligands disclosed herein are capable of universal and subtype-specific biorecognition.

The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue via 18F-labeled peptide ligands disclosed herein.

An affinity membrane separator is provided that includes a separation substrate with a plurality of peptide ligands positioned thereon. The peptide ligands preferentially bind to one of a nucleic acid product and a waste nucleic acid product, e.g., produced by a mRNA synthesis bioreactor. The peptide ligands include fewer than 20 residues and at least one defined secondary structure, and have a global charge greater than about 1 and at least one lysine, arginine, or glutamine residue in order to preferentially bind ds-RNA relative to ss-RNA, or a global charge less than about 0 and at least one serine or asparagine residue in order to preferentially bind ss-RNA relative to ds-RNA. Peptide ligands can advantageously bind to ds-RNA byproducts from the production of ss-RNA vaccines, e.g., against SARS-CoV-2, while allowing the ss-RNA vaccines themselves to pass through the separator, providing an efficient system for production of purified ss-RNA vaccine products.

To provide a new conjugate usable for photoimmunotherapy.SOLUTION: The conjugate of the present disclosure comprises an epidermal growth factor receptor (EGFR) peptide ligand and a photosensitive dye, wherein said photosensitive dye is conjugated to said EGFR peptide ligand via a linker, wherein the backbone length of said linker is between 14 and 55 atoms.SELECTED DRAWING: Figure 5

The application discloses a biased polypeptide ligand of protease-activated receptor 2 and application thereof, and belongs to the technical field of proteins and polypeptides. The application aims to provide a biased polypeptide ligand of protease-activated receptor 2, which only activates the Gq signal pathway of PAR2. The application provides a biased polypeptide ligand of protease-activated receptor 2, which is obtained by any one or both of mutation and modification of amino acids of SLIGRL-NH2 as a starting sequence. The biased PAR2 polypeptide ligand designed in the application has unique advantages in treating diseases caused by nerve injury.

The invention relates to the technical field of chemical synthesis of medicines, in particular to a peptide compound, a peptide ligand, a peptide complex and application thereof. The peptide compound as well as the peptide ligand and the peptide complex thereof provided by the invention have remarkable uPAR targeting specificity and excellent uPAR affinity, which indicates that the peptide compound, the peptide ligand and the peptide complex can act on related diseases with high uPAR expression, or can be used as carriers to carry nuclides to be accurately delivered to tumor sites, so that the treatment effect is improved. The peptide compounds, the peptide ligands and the peptide complexes have the advantages that uPAR targeting specificity is remarkable, and a novel clinical solution is provided for accurate diagnosis and treatment of uPAR high-expression tumors.

The application discloses a polypeptide ligand SR-22 targeting a membrane protein of a pathogenic oomycete and an application thereof, and the amino acid sequence of the polypeptide ligand SR-22 is SRITRLLRGSGSGSSRITRLLR. The polypeptide ligand SR-22 provided by the application can significantly inhibit the growth of various crop pathogenic oomycetes, and can well inhibit the infection of pathogenic bacteria and prevent the occurrence of diseases in practical application, and can be developed into a novel targeted polypeptide pesticide for green prevention and control of crop oomycete diseases.

The application discloses a broad-spectrum affinity peptide ligand for influenza vaccine separation and purification and application thereof. The broad-spectrum affinity peptide ligand contains an amino acid sequence which is combined with the conserved structural units 130-loop, 150-loop and 190-helix of the hemagglutinin receptor binding site of an influenza virus, and the amino acid sequence is R 1 -R 2 -R 3 -(R 4 )3-R 5 -(R 4 )2-R 6 -R 7 -R 8 , R 1 is any one of glutamic acid, arginine, histidine and proline, R 2 is tryptophan, R 3 is any one of tyrosine and phenylalanine, R 4 is glycine, R 5 is any one of tryptophan, tyrosine and phenylalanine, R 6 is any one of glutamic acid, histidine, glutamine and tyrosine, R 7 is any one of tryptophan and phenylalanine, and R 8 is proline. The broad-spectrum affinity peptide ligand has high broad-spectrum affinity, and the broad-spectrum affinity chromatography medium can obtain the influenza vaccine with high purity and yield, and has great potential in application to the separation and purification process of the influenza vaccine.